News

This filing provides a legal basis for subsequent market transactions, with the resale scale accounting for a certain proportion of the company’s circulating shares. The document shows that the transaction will be conducted through public market channels, and the specific sale time and price will be determined according to market conditions. As a biopharmaceutical company focused on gene therapy research and development, Solid Biosciences has recently experienced significant stock price fluctuations. This shareholder reduction plan may have some impact on the liquidity of the secondary market, and investors should pay attention to subsequent changes in shareholding.

According to its latest financial forecasting model, by 2030 the company's net profit and earnings per share are expected to nearly triple. This strong growth outlook highlights the synergistic effect of the company's strategic transformation and expansion in the technology education sector. Notably, the forecasted figures represent a leap from current levels, reflecting management's confidence in increased penetration of the vocational education market and business diversification. By optimizing course structures and expanding school-enterprise cooperation networks, the company continues to strengthen its differentiated competitive advantage in the skills training field. Investors will closely monitor subsequent quarterly financial reports to assess their support for the company's long-term goals.

The company has officially appointed Ms. Melissa Orilall as Chief Financial Officer, with the appointment set to take effect on March 13, 2026. This executive change has been disclosed through relevant filings with the U.S. Securities and Exchange Commission, marking a new phase in the company's financial strategic management.